Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENCNASDAQ:GRNANASDAQ:INBXNASDAQ:INMB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$7.86+1.8%$6.90$3.96▼$8.72$216.94M0.495,331 shs47,850 shsGRNAGreenLight Biosciences$0.30$0.30$0.18▼$5.90$45.43M1.44486,986 shs732 shsINBXInhibrx Biosciences$15.21+4.2%$12.73$10.80▼$17.79$220.18MN/A104,110 shs53,361 shsINMBINmune Bio$7.24+5.4%$7.54$4.32▼$10.50$166.40M1.55298,886 shs1.00 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies0.00%-5.53%-3.79%+17.84%+18.20%GRNAGreenLight Biosciences0.00%0.00%0.00%0.00%0.00%INBXInhibrx Biosciences0.00%+6.14%+16.37%+5.99%+4.39%INMBINmune Bio0.00%-8.59%-5.73%-10.84%-5.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFENCAdherex Technologies2.0531 of 5 stars3.62.00.00.00.63.30.0GRNAGreenLight BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AINBXInhibrx Biosciences2.4155 of 5 stars0.03.00.04.60.02.51.3INMBINmune Bio1.6709 of 5 stars3.60.00.00.01.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCAdherex Technologies 3.25Buy$13.0065.39% UpsideGRNAGreenLight Biosciences 0.00N/AN/AN/AINBXInhibrx Biosciences 2.00HoldN/AN/AINMBINmune Bio 3.17Buy$22.80214.92% UpsideCurrent Analyst Ratings BreakdownLatest GRNA, INMB, FENC, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/14/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCAdherex Technologies$47.54M4.56$0.03 per share243.38($0.21) per share-37.43GRNAGreenLight Biosciences$10.20M4.45N/AN/A$0.32 per share0.94INBXInhibrx Biosciences$200K1,101.20$117.00 per share0.13$9.23 per share1.65INMBINmune Bio$10K16,637.52N/AN/A$1.45 per share4.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCAdherex Technologies-$440K-$0.51N/AN/AN/A-45.52%N/A-26.37%8/12/2025 (Estimated)GRNAGreenLight Biosciences-$167.05M-$1.14N/A∞N/A-1,521.00%-374.26%-122.78%N/AINBXInhibrx Biosciences$1.69B$116.750.13N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)INMBINmune Bio-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)Latest GRNA, INMB, FENC, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/13/2025Q1 2025FENCAdherex Technologies-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFENCAdherex TechnologiesN/AN/AN/AN/AN/AGRNAGreenLight BiosciencesN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCAdherex TechnologiesN/A5.134.97GRNAGreenLight Biosciences0.491.211.21INBXInhibrx Biosciences1.045.125.12INMBINmune BioN/A2.642.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCAdherex Technologies55.51%GRNAGreenLight Biosciences24.41%INBXInhibrx Biosciences82.46%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipFENCAdherex Technologies11.76%GRNAGreenLight Biosciences30.30%INBXInhibrx Biosciences17.09%INMBINmune Bio35.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCAdherex TechnologiesN/A27.60 million24.35 millionOptionableGRNAGreenLight Biosciences280151.68 million105.72 millionNot OptionableINBXInhibrx Biosciences16614.48 million12.00 millionOptionableINMBINmune Bio1022.98 million14.78 millionOptionableGRNA, INMB, FENC, and INBX HeadlinesRecent News About These CompaniesINmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative OpportunityJune 16, 2025 | seekingalpha.comINmune Bio, Inc. Collaborates on Study Showing XPro™ Treatment Reduces Alzheimer’s-like Pathology After Traumatic Brain Injury in MiceJune 12, 2025 | nasdaq.comINmune Bio, Inc. (NASDAQ:INMB) Shares Bought by Two Sigma Investments LPJune 11, 2025 | marketbeat.comMillennium Management LLC Boosts Stake in INmune Bio, Inc. (NASDAQ:INMB)June 4, 2025 | marketbeat.comINmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big OpportunityMay 15, 2025 | seekingalpha.comINmune Bio, Inc. (INMB) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comINmune Bio appoints new accounting firmMay 9, 2025 | investing.comINmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business UpdateMay 9, 2025 | finanznachrichten.deINmune Bio Inc. Announces First Quarter 2025 Results and Provides Business UpdateMay 8, 2025 | globenewswire.comINmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8thMay 5, 2025 | globenewswire.comINmune Bio to receive US patent for next-generation mesenchymal stromal cell product, CORDStromApril 19, 2025 | pharmabiz.comINmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform TechnologyApril 16, 2025 | markets.businessinsider.comINmune Bio receives favorable patentability opinion for CORDStrom platformApril 16, 2025 | markets.businessinsider.comINmune Bio partners with Cell, Gene Therapy Catapult to scale up CORDStromApril 14, 2025 | markets.businessinsider.comINmune Bio Partners with Cell and Gene Therapy CatapultApril 14, 2025 | msn.comINmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial ReadinessApril 14, 2025 | globenewswire.comINmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II StudyApril 1, 2025 | markets.businessinsider.comINmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2024 Results and Provides a Business UpdateMarch 29, 2025 | finanznachrichten.deScotiabank Remains a Buy on Inmune Bio (INMB)March 29, 2025 | markets.businessinsider.comAlliance Global Partners Reaffirms Their Buy Rating on Inmune Bio (INMB)March 29, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRNA, INMB, FENC, and INBX Company DescriptionsAdherex Technologies NASDAQ:FENC$7.86 +0.14 (+1.81%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$7.86 +0.00 (+0.06%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.GreenLight Biosciences NASDAQ:GRNAFUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.Inhibrx Biosciences NASDAQ:INBX$15.21 +0.61 (+4.18%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$15.25 +0.04 (+0.26%) As of 06/18/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.INmune Bio NASDAQ:INMB$7.24 +0.37 (+5.39%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$7.22 -0.03 (-0.35%) As of 06/18/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
